Profile data is unavailable for this security.
About the company
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
- Revenue in USD (TTM)0.00
- Net income in USD-33.74m
- Incorporated1997
- Employees25.00
- LocationNuCana PLCLochside House, 3 Lochside WayEDINBURGH EH12 9DTUnited KingdomGBR
- Phone+44 131 248 3660
- Fax+44 131 248 3001
- Websitehttps://www.nucana.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TFF Pharmaceuticals Inc | 885.71k | -19.93m | 6.01m | 19.00 | -- | 0.9214 | -- | 6.79 | -10.20 | -10.20 | 0.4371 | 2.11 | 0.0647 | -- | 3.72 | 46,616.32 | -145.46 | -79.57 | -181.57 | -83.41 | -- | -- | -2,249.83 | -8,687.66 | -- | -- | 0.00 | -- | 48.01 | -- | 33.13 | -- | -- | -- |
| Hepion Pharmaceuticals Inc | 0.00 | -38.52m | 6.07m | 22.00 | -- | 1.04 | -- | -- | -9.49 | -9.49 | 0.00 | 1.37 | 0.00 | -- | -- | 0.00 | -117.64 | -61.43 | -145.05 | -68.82 | -- | -- | -- | -- | -- | -3,240.31 | 0.00 | -- | -- | -- | -7.92 | -- | -- | -- |
| Notable Labs Ltd | 311.00k | -12.39m | 6.13m | 16.00 | -- | 0.5312 | -- | 19.72 | -2.31 | -2.31 | 0.0622 | 1.28 | 0.0142 | -- | -- | 19,437.50 | -56.70 | -52.02 | -74.10 | -62.09 | 37.30 | 60.19 | -3,984.24 | -3,636.93 | -- | -- | 0.0271 | -- | -52.89 | -11.93 | 65.13 | -- | -50.69 | -- |
| Tenax Therapeutics Inc | 0.00 | -10.10m | 6.15m | 5.00 | -- | 0.4947 | -- | -- | -24.52 | -24.52 | 0.00 | 6.35 | 0.00 | -- | -- | 0.00 | -67.96 | -199.16 | -75.66 | -285.64 | -- | -- | -- | -- | -- | -105.12 | 0.0322 | -- | -- | -- | 30.21 | -- | -- | -- |
| Glucose Health Inc | 1.11m | -456.46k | 6.19m | 2.00 | -- | 6.53 | -- | 5.56 | -0.033 | -0.033 | 0.0803 | 0.0561 | -- | -- | -- | -- | -- | -86.94 | -- | -153.95 | 47.19 | 40.68 | -31.99 | -56.93 | 313.11 | -- | 0.00 | -- | 98.39 | 24.94 | 16.87 | -- | -- | -- |
| BioCardia Inc | 468.00k | -10.34m | 6.21m | 16.00 | -- | -- | -- | 13.26 | -7.04 | -7.04 | 0.3132 | -1.27 | 0.0954 | -- | 4.44 | 29,250.00 | -210.81 | -107.34 | -1,190.90 | -154.17 | -- | -- | -2,208.76 | -1,779.24 | -- | -- | -- | -- | -64.72 | -5.26 | 2.82 | -- | -28.89 | -- |
| GT Biopharma Inc | 0.00 | -9.64m | 6.23m | 2.00 | -- | 0.7513 | -- | -- | -7.04 | -7.04 | 0.00 | 3.85 | 0.00 | -- | -- | 0.00 | -64.24 | -205.36 | -90.39 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 63.62 | -- | -- | -- |
| Kineta Inc | 5.16m | -17.89m | 6.24m | 11.00 | -- | -- | -- | 1.21 | -1.55 | -1.55 | 0.4673 | -0.564 | 0.6667 | -- | -- | 469,181.80 | -230.51 | -66.16 | -- | -86.61 | -- | -- | -345.77 | -854.74 | -- | -- | -- | -- | 178.65 | 13.89 | 77.76 | -- | -- | -- |
| Sunshine Biopharma Inc | 26.74m | -4.09m | 6.25m | 44.00 | -- | 0.0132 | -- | 0.2338 | -13.35 | -13.35 | 76.96 | 24.96 | 0.9081 | 3.13 | 11.58 | 607,722.50 | -13.88 | -101.52 | -17.99 | -137.04 | 33.15 | 35.47 | -15.29 | -165.33 | 3.23 | -- | 0.00 | -- | 454.42 | -- | 83.15 | -- | 110.99 | -- |
| NuCana PLC (ADR) | 0.00 | -33.74m | 6.34m | 25.00 | -- | 0.5312 | -- | -- | -301.53 | -301.53 | 0.00 | 5.65 | 0.00 | -- | -- | 0.00 | -72.34 | -41.01 | -125.17 | -48.07 | -- | -- | -- | -- | -- | -- | 0.0324 | -- | -- | -- | 13.71 | -- | -21.70 | -- |
| Titan Pharmaceuticals Inc | 87.00k | -4.95m | 6.34m | 4.00 | -- | 1.04 | -- | 72.93 | -6.41 | -6.41 | 0.1119 | 6.66 | 0.0197 | -- | 1.23 | 21,750.00 | -112.41 | -96.80 | -170.59 | -156.65 | -- | -- | -5,694.25 | -406.26 | -- | -415.19 | 0.00 | -- | -66.97 | -51.16 | 45.43 | -- | -65.61 | -- |
| Intelligent Bio Solutions Inc | 2.83m | -10.03m | 6.42m | 17.00 | -- | 0.5392 | -- | 2.27 | -64.14 | -64.14 | 4.60 | 3.82 | 0.2041 | 2.69 | 7.77 | 166,299.40 | -72.67 | -80.65 | -107.67 | -224.84 | 23.33 | -- | -356.09 | -948.54 | 1.87 | -- | 0.0451 | -- | 187.51 | 367.97 | -28.00 | -- | -- | -- |
| Virios Therapeutics Inc | 0.00 | -5.07m | 6.61m | 4.00 | -- | -- | -- | -- | -0.2673 | -0.2673 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 56.76 | -- | -- | -- |
| 22nd Century Group Inc | 29.75m | -62.89m | 6.70m | 64.00 | -- | -- | -- | 0.2252 | -40.02 | -97.93 | 17.94 | -3.23 | 0.40 | 5.90 | 5.47 | 464,796.90 | -66.29 | -46.78 | -92.49 | -54.18 | -33.09 | -2.11 | -165.75 | -107.95 | 0.4284 | -3.67 | 4.76 | -- | -20.49 | 4.03 | -76.94 | -- | 53.60 | -- |
| Integrated BioPharma, Inc. | 50.57m | -116.00k | 6.72m | 141.00 | -- | 0.3552 | 31.68 | 0.1328 | -0.0041 | -0.0041 | 1.67 | 0.6283 | 1.88 | 4.45 | 10.76 | 358,617.00 | -0.431 | 15.51 | -0.5698 | 27.94 | 7.09 | 12.09 | -0.2294 | 6.44 | 1.02 | -9.00 | 0.001 | -- | -9.91 | 3.00 | -101.35 | -- | -14.03 | -- |
Data as of Jun 14 2024. Currency figures normalised to NuCana PLC's reporting currency: US Dollar USD
2.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Acadian Asset Management LLCas of 31 Mar 2024 | 23.63k | 1.14% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 16.83k | 0.81% |
| HRK LUNIS AGas of 30 Dec 2022 | 8.80k | 0.43% |
| Citadel Securities LLCas of 31 Mar 2024 | 3.57k | 0.17% |
| HRT Financial LLCas of 31 Mar 2024 | 1.34k | 0.07% |
| Edmond de Rothschild (Suisse) SA (Private Banking)as of 31 Mar 2024 | 1.00k | 0.05% |
| Horizon Kinetics Asset Management LLCas of 31 Mar 2024 | 779.00 | 0.04% |
| Geode Capital Management LLCas of 31 Mar 2024 | 751.00 | 0.04% |
| G1 Execution Services LLCas of 31 Mar 2024 | 566.00 | 0.03% |
| BNP Paribas Financial Marketsas of 31 Mar 2024 | 500.00 | 0.02% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
